Macrogenics, Inc. · NASDAQ:MGNX
Macrogenics — Investor Presentation (December 2020)
14 slides from Macrogenics's investor presentation, Dec 17, 2020
Slide 1: Now Approved
® NOW APPROVED December 17, 2020
Slide 2: Legal Notices
Legal Notices The information in this slide deck is current as of December 17, 2020, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics’ Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information h
Slide 3: MARGENZA — Now Approved
MARGENZA — Now Approved MARGENZA is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. Se
Slide 4: Designed to Increase Anti-tumor Immune Responses Through Fc-Engineering
Designed to Increase Anti-tumor Immune Responses Through Fc-Engineering Direct Anti-tumor Activity • Inhibits tumor cell proliferation • Reduces shedding of HER2 extracellular domain * Fc Region (5 amino acid mutations) Proprietary Fc Optimization Platform: • Increased binding to CD16A (activating)
Slide 5: MARGENZA Approval Based on Results of SOPHIA
MARGENZA Approval Based on Results of SOPHIA Improved PFS vs. Herceptin®, both with chemotherapy, in pretreated HER2+ metastatic breast cancer Efficacy Safety • 24% Reduction in risk of disease progression or • Boxed Warning for left ventricular dysfunction and death (HR=0.76, p=0.033) embryo-fetal
Slide 6: Rapidly Evolving HER2+ Metastatic Breast Cancer Treatment Landscape
Rapidly Evolving HER2+ Metastatic Breast Cancer Treatment Landscape Oncologists will consider specific patient attributes for sequencing of therapies 1L 2L 3L 4L 5L+ HER2+ mBC 9,500 6,500 3,700 1,500 1,800 Patients(a) 7,000 1L & 2L Therapy Options 3L+Therapy Options trastuzumab + trastuzumab Recentl
Slide 7: MARGENZA with Chemotherapy in Treatment of Pretreated HER2+ mBC
MARGENZA with Chemotherapy in Treatment of Pretreated HER2+ mBC Majority of patients will experience Efficacy disease progression PFS improvement vs. trastuzumab in head-to-head trial Some patients may not be able to tolerate certain therapies MARGENZA may offer… Flexibility Tolerability Ability to
Slide 8: Leveraging EVERSANA's Expertise to Support Commercialization
Leveraging EVERSANA’s Expertise to Support Commercialization Patient Services Clinical & Commercial Data & Field Solutions & Analytics Training Medical Third Party Information & Logistics Medical Affairs • Full integrated launch & commercialization engine Health Economics • End-to-end commercial Mar
Slide 9: Fully Aligned & Engaged with EVERSANA to Support Anticipated March Launch
Fully Aligned & Engaged with EVERSANA to Support Anticipated March Launch Innovative risk-sharing structure provides balance of flexibility and control • Books sales and controls decision-making • Provides access to its broad spectrum of • Leads execution of all development and commercialization ser
Slide 10: Partnership Enables MacroGenics to Execute Strategic Launch Imperatives
Partnership Enables MacroGenics to Execute Strategic Launch Imperatives Establish MARGENZA's role in treatment paradigm Ensure appropriate and affordable access for patients Account for changing dynamics resulting from COVID-19 Preserve anticipated cash runway into 2023 10 December 17, 2020
Slide 11: MARGENZA's Commercialization Anticipated in March 2021
MARGENZA’s Commercialization Anticipated in March 2021 Product Approved Commercial Launch December 16, 2020 March 2021 Launch “Now Approved” website Ready to distribute product Establish distribution network Commercial and medical field teams in place Recruit field teams Patient access s
Slide 12: Evaluating MARGENZA Across HER2+ Diseases
Evaluating MARGENZA Across HER2+ Diseases 2024+ 2020 2021- 2023 Potential Future Studies Ongoing Studies • Earlier line metastatic Initial Approval • 1L Gastric cancer breast cancer in • Pretreated HER2+ metastatic • Neo-adjuvant breast cancer IST F-carriers breast cancer (w/chemo) • Tebotelimab c
Slide 13: Resourced to Support Innovative Pipeline into 2023
Resourced to Support Innovative Pipeline into 2023 Proof-of- Program First-in-Human Concept (Target) Potential Indication(s) (Phase 1) (Phase 2) Pivotal Approved Major Market Rights HER2+ Breast Greater China Margetuximab (HER2) HER2+ GC/GEJ (+retifanlimab/tebotelimab) Flotetuzumab Refractory AML (C
Slide 14: Important Safety Information
Important Safety Information WARNING: LEFT VENTRICULAR DYSFUNCTION AND EMBRYO-FETAL TOXICITY • Left Ventricular Dysfunction: MARGENZA may lead to reductions in left ventricular ejection fraction (LVEF). Evaluate cardiac function prior to and during treatment. Discontinue MARGENZA treatment for a con